Effect of ketamine on anxiety ratings in patients with anxiety disorders

Phases 1–2 evaluate within-subject ascending single subcutaneous ketamine doses (0.25, 0.5, 1 mg/kg) with ~1 week between doses; Phase 1 open‑label, Phase 2 double‑blind with midazolam active control.

Phase 3 offers maintenance ketamine (1–2× weekly for up to 3 months) to participants achieving ≥50% reduction in anxiety. Outcomes include change in HAM‑A/SSAI/LSAS at predose, 1h, 2h, 24h (primary), 72h and 168h; safety via vital signs and monitoring up to 24h post-dose.